E83.52 Insurance Policy Changes

ICD-10 E83.52 is officially defined as "Hypercalcemia." code E83.52 is referenced in 6 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E83.52 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Vitamin D Testing
Serum measurement of vitamin D (25-hydroxyvitamin D [25(OH)D], CPT 82306) is considered medically necessary up to four times per calendar year for the following conditions, among others: biliary cirrhosis, celiac disease, hypercalcemia or hypocalcemia, hyperparathyroidism or hypoparathyroidism, intestinal malabsorption, liver cirrhosis, long-term use of anticonvulsants, glucocorticoids or other medications known to lower vitamin D levels, malnutrition, osteomalacia, osteoporosis, rickets, sarcoidosis, stage III-V chronic kidney disease and end stage renal disease, and vitamin D deficiency on replacement therapy to monitor treatment efficacy. Routine serum vitamin D testing performed for screening purposes in asymptomatic patients is considered not medically necessary. Intestinal failure-associated liver disease (ICD-10 K76.83) is listed as a new diagnosis code effective 10/01/2026.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Chelation Therapy
Chelation therapy is considered medically necessary when based on blood levels and used to treat chronic iron overload due to blood transfusions or nontransfusion-dependent thalassemia, extreme conditions of metal toxicity, lead poisoning, Wilson's disease, emergency treatment of hypercalcemia, or control of ventricular arrhythmias or heart block associated with digitalis toxicity. Off-label applications, including atherosclerosis, Alzheimer disease, arthritis, multiple sclerosis, diabetes, autism, and Parkinson disease, are considered investigational. The 08/06/2026 review added Parkinson disease to the investigational list, and the 10/01/2026 update added ICD-10 codes R78.72 and Z77.013 to the code reference.
Aetna · Identified Oct 10, 2026Medium impact
Repository Corticotropin Injection (Acthar Gel and Purified Cortrophin Gel) (CPB 0762, reviewed 2026-10-08)
Aetna considers repository corticotropin injection (Acthar Gel only) medically necessary for infantile spasms in members less than 2 years of age, and considers all other indications experimental, investigational, unproven, or not medically necessary. Precertification of Acthar Gel or Purified Cortrophin Gel is required of all Aetna participating providers and members in applicable plan designs. Purified Cortrophin Gel is considered experimental, investigational, or unproven for infantile spasms because it is not FDA-approved, nor has a compendial use, for this indication, and use of Acthar Gel in combination with Purified Cortrophin Gel is considered experimental, investigational, or unproven.
Aetna · Identified Sep 30, 2026Medium impact
Denosumab (CPB 0804, reviewed 2026-08-21)
Aetna covers Prolia and its ten listed biosimilars, and Xgeva and its nine listed biosimilars, under commercial medical plans, and precertification is required for these denosumab products in applicable plan designs. Prolia is considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and inhibiting progression of bone erosion in rheumatoid arthritis, based on criteria such as fragility fracture history, pre-treatment T-score, pre-treatment FRAX probability, and prior therapy response or intolerance. Xgeva is considered medically necessary for multiple myeloma, bone metastases from solid tumors, giant cell tumor of bone, hypercalcemia of malignancy refractory to intravenous bisphosphonate therapy, and second-line therapy for osteopenia or osteoporosis in systemic mastocytosis, and continuation of Xgeva requires disease stability or improvement.
Aetna · Identified Aug 19, 2026Medium impact
Zoledronic Acid (CPB 0524, reviewed 2026-02-12)
Aetna's clinical policy bulletin covers zoledronic acid for commercial medical plans. Zoledronic acid 5 mg (Reclast or generic) is considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget's disease of bone, and treatment-related bone loss in men with prostate cancer receiving androgen deprivation therapy, when the listed criteria are met. Zoledronic acid 4 mg (formerly branded Zometa) is considered medically necessary for bone metastases from a solid tumor, certain breast cancer indications, hypercalcemia of malignancy, Langerhans cell histiocytosis with bone disease, multiple myeloma, and systemic mastocytosis with osteopenia or osteoporosis. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Denosumab (CPB 0804, reviewed 2026-06-08)
Aetna's commercial medical policy sets coverage criteria for Prolia and its biosimilars and for Xgeva and its biosimilars, and precertification is required for these products in applicable plan designs. Prolia and its biosimilars are considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and inhibiting progression of bone erosion in rheumatoid arthritis. Xgeva and its biosimilars are considered medically necessary for multiple myeloma, bone metastases from a solid tumor, giant cell tumor of bone, hypercalcemia of malignancy refractory to intravenous bisphosphonate therapy, and second-line therapy for osteopenia or osteoporosis in systemic mastocytosis. All other indications are considered experimental, investigational, or unproven, and combination therapy of denosumab with intravenous bisphosphonates is also considered experimental, investigational, or unproven.

Watch E83.52

Get one email when a payer policy names E83.52, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code E83.52?

There are 6 tracked policy changes affecting code E83.52, including updates from Blue Cross & Blue Shield of Mississippi, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E83.52?

Payers that have issued tracked updates for code E83.52 include: Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code E83.52 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E83.52. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E83.52?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Vitamin D Testing

Chelation Therapy

Repository Corticotropin Injection (Acthar Gel and Purified Cortrophin Gel) (CPB 0762, reviewed 2026-10-08)

Denosumab (CPB 0804, reviewed 2026-08-21)

Zoledronic Acid (CPB 0524, reviewed 2026-02-12)

Denosumab (CPB 0804, reviewed 2026-06-08)

What insurance policy changes affect code E83.52?

Which payers have updated policy for code E83.52?

How do I get notified when code E83.52 policy changes?

Why do payers change policies for code E83.52?